Searched for
TILDRAKIZUMAB
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...- Sun Pharma most exposed Indian company to Trump's new tariff threat, warns JefferiesIndian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...
- Sun Pharma’s Ilumya expansion bid gets USFDA nod for reviewSun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for t...
- Sun Pharma launches Ilumya for psoriasis treatment in IndiaSun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....
- Sun Pharma brings global psoriasis drug ILUMYA to Indian marketSun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...
- Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement listThe inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs ...
- Sun Pharma erases gains to close in the redShares of Sun Pharma closed 0.45 per cent down at Rs 401 on BSE.
- Sun Pharma arm enters pact with China Medical SystemChina Medical System will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, t...
- Sun Pharma jumps 2% as partner gets drug nodThe stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drugThe novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the con...
- Sun Pharma inks $55.5-mn deal for anti-psoriasis drugSun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential.
- US FDA accepts application for psoriasis drug: Sun PharmaThe FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March ...
- Almirall seeks nod for tildrakizumab in Europe: Sun PharmaThe filing includes efficacy and safety data from the pivotal Phase III clinical trials that included over 1,800 patients across more than ...
- Sun Pharma announces details of psoriasis drug trialsTildrakizumab is a monoclonal antibody designed to control the pathogenic cells responsible for the inflammatory process of psoriasis with ...
- Sun Pharma signs licening pact with spanish firm Almirall for psoriasis drugIn return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...
- Sun Pharma Q2 net profit up 15% at Rs 1,572 crore"We also continue to review opportunities to expand and strengthen our global footprint,” said Dilip Shanghvi, managing director, Sun Pharm...
- Sun Pharmaceutical shares end nearly 2 per cent up on Merck & Co Inc licensing pactStock of the pharma firm settled with a gain of 1.63 per cent at Rs 805.20 on the BSE. During the day, it climbed 2.78 per cent to Rs 814.4...
- Sun Pharma signs pact with Merck; stock gainsTildrakizumab is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.
- Sun Pharma, Merck & Co Inc enter into pact for TildrakizumabUnder terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck.
Load More
